Croda and AAHI enter vaccine adjuvant formulations partnership
20 Mar 2024
Vaccine
Preview
Source: Pharmaceutical Technology
Croda and the AAHI aim to accelerate the development of new adjuvants and formulations. Credit: Momentum studio via Shutterstock.
Croda International has entered a collaboration agreement with the Access to Advanced Health Institute (AAHI) to innovate and develop vaccine adjuvant formulations.
Under this deal, the parties will use their combined capabilities to make new vaccine adjuvants accessible worldwide. This approach will aid in the advancement of next-generation vaccines that are robust and durable.
The AAHI has platform technologies designed to harness the immune system in fighting diseases.
In addition, the institute has an adjuvant formulation portfolio used in numerous vaccine candidates for fighting major infectious and neglected ailments identified by the World Health Organization (WHO) as global threats.
The exclusive agreement between the AAHI and Croda encompasses joint research and development efforts.
See Also:
Cancer Research UK and CRIS fund lung cancer vaccine research
Preview
Source: Pharmaceutical Technology
Zydus Lifesciences files patent for liquid oral formulation of sildenafil for various diseases
Preview
Source: Pharmaceutical Technology
By combining their expertise, the parties are set to accelerate the quick development of new adjuvants and formulations.
They also plan to establish efficient manufacturing processes for large-scale production to meet the demands of the vaccine industry and global health needs.
Under the partnership, Croda will gain specific rights for the marketing, distribution, and sale of selected new adjuvant formulations that are developed by the AAHI.
These formulations are intended for research purposes and clinical development.
Croda will become the AAHI’s exclusive authorised manufacturer in various countries to scale up manufacturing processes, providing support for Phase III trials and commercial usage.
Croda Life Sciences president Daniele Piergentili said: “This partnership marks another significant milestone in our endeavour to offer a comprehensive portfolio of adjuvants for the vaccines of tomorrow.
“It perfectly aligns with our pharmaceutical strategy to ‘Empower biologics delivery’ and underscores our commitment to making substantial contributions to the successful development and commercialisation of WHO-listed pipeline vaccines.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.